---
title: Antipsychotics
module: "antipsychotics"
---

 * **1.** [Introduction](CON155606_2)
 * **1.1** [Class members](CON155606_3)
 * **2.** [Prescribing points](CON155606_4)
	 + **2.1** [Adherence to treatment](CON155606_5)
	 + **2.2** [Children and adolescents](CON155606_6)
 * **3.** [Principal risks and risk-reduction measures](CON155606_7)
	 + **3.1** [Gastrointestinal adverse effects](CON155606_8)
	 + **3.2** [Central nervous system adverse effects](CON143740_9)
		 - **3.2.1** [Sedation and sleep disturbances](CON155606_10)
		 - **3.2.2** [Extrapyramidal side effects: introduction](CON155606_11)
			 * **3.2.2.1** [Extrapyramidal side effects: acute dystonia](CON155606_12)
			 * **3.2.2.2** [Extrapyramidal side effects: akathisia](CON155606_13)
			 * **3.2.2.3** [Extrapyramidal side effects: parkinsonism](CON155606_14)
			 * **3.2.2.4** [Extrapyramidal side effects: tardive dyskinesia](CON155606_15)
		 - **3.2.3** [Neuroleptic malignant syndrome](CON155606_16)
		 - **3.2.4** [Convulsions](CON155606_17)
	 + **3.3** [Cardiovascular adverse effects](CON155606_18)
		 - **3.3.1** [Blood pressure changes](CON155606_19)
		 - **3.3.2** [Cerebrovascular events such as stroke](CON155606_20)
		 - **3.3.3** [Cardiac rhythm disordersâ€”QT interval prolongation](CON155606_21)
		 - **3.3.4** [Venous thromboembolism](CON155606_21)
	 + **3.4** [Metabolic adverse effects](CON155606_23)
	 + **3.5** [Hyperprolactinaemia and sexual adverse effects](CON155606_24)
	 + **3.6** [Blood disorders](CON155606_25)
	 + **3.7** [Temperature regulation](CON155606_26)
	 + **3.8** [Adverse effects on the skin](CON155606_27)
	 + **3.9** [Adverse effects on the eye](CON155606_28)
	 + **3.10** [Antimuscarinic adverse effects](CON155606_29)
	 + **3.11** [Dependence and withdrawal](CON155606_30)
	 + **3.12** [Important drug interactions](CON155606_31)
 * **4.** [Precautions and risks associated with special uses of antipsychotics](CON155606_32)
	 + **4.1** [Elderly patients with dementia](CON155606_33)
	 + **4.2** [Pregnancy and breastfeeding](CON155606_34)
	 + **4.3** [Prolonged-release antipsychotic injections](CON155606_35)
	 + **4.4** [Antipsychotic injections for immediate effect](CON155606_36)
	 + **4.5** [Clozapine](CON155606_37)
 * **5.** [Key points](CON155606_38)
 * **6.** [Further information](CON155606_39)
 * **7.** [Summary of licensed indications of antipsychotics for adults](CON155606_40)
 * **8.** [Classification of antipsychotics](CON155606_41)
 * **9.** [Structural formulae of selected antipsychotics](CON155606_42)
 * **10.** [Self-assessment questions](CON155606_43)
	 + **10.1** [Feedback on self-assessment questions](CON155606_44)
 * **11.** [Glossary](CON155606_45)
 * **12.** [Module evaluation](CON155606_46)
